Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.70 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.70 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | CA6 | P23280 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071837 | 0.90 | PTGS2 (0.71) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5069872 | 0.89 | PTGS2 (0.72) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5074525 | 0.88 | PTGS2 (0.69) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5073588 | 0.87 | PTGS2 (0.81) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071029 | 0.85 | PTGS2 (0.77) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5069873 | 0.85 | PTGS2 (0.77) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL8910383 | 0.85 | PTGS2 (0.64) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL8345961 | 0.83 | PTGS2 (0.65) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071829 | 0.83 | PTGS2 (0.78) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071849 | 0.83 | PTGS2 (0.74) | PTGS2NR4A2MT-CO2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7420061-B2 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PHARMACIA CORPORATION | 2005-02-10 | — | — | US | disclosed |
| US-6815460-B2 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-5932598-A | NOVEL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PRODRUGS; ADMINISTERING TO TREAT INFLAMMATION-ASSOCIATED PAIN DUE TO CANCER, DENTAL PAIN; CYCLOOXYGENASE-2 INHIBITORS | G. D. SEARLE & CO. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | PTGS2 1/4885NR4A2 978/4885MT-CO2 2100/4885 |
| US-20050032851-A1 | Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors | PTGS2, PTGES2, PTGES | PTGS2 1/4885NR4A2 904/4885MT-CO2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.